Cited by 337Monoclonal and Polyclonal Antibodies ResearchT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

Perez, Pilar, Hoffman, Robert W., Shaw, Stephen, Bluestone, Jeffrey A., Segal, David M.·1985·Nature

Open this paper in CoChat — free account

Abstract

The specificity of cytotoxic T lymphocytes (Tc) cells is conferred by an antigen-specific receptor, Ti, which in humans is physically associated with an invariant cell-surface glycoprotein, T3. Monoclonal antibodies specific for either T3 and Ti are able to elicit a variety of T-cell responses such as lymphokine production, mitogenesis and cytotoxicity. For example, human Tc cells lyse anti-T3-expressing hybridoma cells, but not cells of other specificity, presumably because anti-T3 on the hybridoma cells binds to T3 on the Tc cells and triggers lysis. Here, we have adapted approaches used in a different cytotoxic effector system, antibody-dependent cellular cytotoxicity (ADCC), to alter the specificity of Tc cell. Studies of ADCC showed that heteroaggregates containing anti-Fc receptor (Fc gamma R) antibody cross-linked to a second antibody bind to Fc gamma R on ADCC effectors and cause them to kill target cells bearing antigen recognized by the second antibody. The present studies use anti-T3-containing heteroaggregates to re-target human Tc cells to cells for which we have appropriate antibodies, including xenogeneic tumour cells and chicken erythrocytes. These results extend previous observations on the role of T3 in triggering cytotoxicity and suggest that effector cell re-targeting could be used for in vivo treatment of neoplasms and other pathogens that express distinctive surface antigens.

Integrity signals

Registry

Crossref · 10.1038/316354a0

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.
Unkeless, J. C. (1979) · The Journal of Experimental Medicine · doi:10.1084/jem.150.3.580 · Cited by 1,271
OKT3: A monoclonal anti-human T lymphocyte antibody with potent mitogenic properties
Wauwe, J. P. V., DeMay, J., & Goossens, J. G. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.125.5.2359.a · Cited by 710
OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.
Wauwe, J. P. V., Mey, J. D., & Goossens, J. (1980) · The Journal of Immunology · doi:10.4049/jimmunol.124.6.2708 · Cited by 582
Hybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492
Antigen-like effects of monoclonal antibodies directed at receptors on human T cell clones.
Meuer, S. C., Hodgdon, J. C., Hussey, R. E., Protentis, J. P., Schlossman, S. F., & Reinherz, E. L. (1983) · The Journal of Experimental Medicine · doi:10.1084/jem.158.3.988 · Cited by 423
The Major Histocompatibility Compex-Restricted Antigen Receptor on T Cells
HASKINS, K. M., Kappler, J. W., & Marrack, P. (1984) · Annual Review of Immunology · doi:10.1146/annurev.iy.02.040184.000411 · Cited by 369
Evidence for a new segregant series of B cell antigens that are encoded in the HLA-D region and that stimulate secondary allogenic proliferative and cytotoxic responses.
Shaw, S., Johnson, A. H., & Shearer, G. M. (1980) · The Journal of Experimental Medicine · doi:10.1084/jem.152.3.565 · Cited by 347
Self-citation
The Human T-Cell Receptor
Meuer, S. C., Acuto, O., Hercend, T., Schlossman, S. F., & Reinherz, E. L. (1984) · Annual Review of Immunology · doi:10.1146/annurev.iy.02.040184.000323 · Cited by 233
Selective inhibition of human T cell cytotoxicity at levels of target recognition or initiation of lysis by monoclonal OKT3 and Leu-2a antibodies.
Landegren, U. D., Ramstedt, U., Axberg, I., Ullberg, M., Jondal, M., & Wigzell, H. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.5.1579 · Cited by 180
Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes.
Kranz, D. M., Tonegawa, S., & Eisen, H. N. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.24.7922 · Cited by 177

Show all 23 references

Research works printed but not linked: 2

Huffman, R. W., Bluestone, J. A., Leo, O. & Shaw, S. J. Immun. (in the press).
Sachs, D. H., Mayer, N. & Ozato, K. in Monoclonal Antibodies and T-Cell Hybridomas (eds Hammerling, G., Hammerling, U. & Kearny, J. F.) 95–101 (Eisevier, New York, 1981).

Sorted by citations

Items 201–300 of 336

Peptide‐antibody conjugates for tumour therapy: A MHC‐class‐II‐restricted tetanus toxin peptide coupled to an anti‐IG light chain antibody can induce cytotoxic lysis of a human B‐cell lymphoma by specific CD4 T cells
Yu, Z., Healy, F., Valmori, D., Escobar, P., Corradin, G., & Mach, J. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560217 · Cited by 14
Lysis of nonnucleated red blood cells by cytotoxic T lymphocytes
Lanzavecchia, A., & Staerz, U. D. (1987) · European Journal of Immunology · doi:10.1002/eji.1830170727 · Cited by 14
Isolation of a thymus-homing Lyt-2−, L3T4− T-cell line from mouse spleen
O'Neill, H. C. (1987) · Cellular Immunology · doi:10.1016/0008-8749(87)90306-6 · Cited by 14
Strategies in antibody therapy of cancer
Wawrzynczak, E. J., & DAVIES, A. J. S. (1990) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1990.tb05425.x · Cited by 13
Target cell death triggered by cytotoxic T lymphocytes: a target cell mutant distinguishes passive pore formation and active cell suicide mechanisms
Ucker, D. S., Wilson, J. D., & Hebshi, L. D. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.1.427 · Cited by 13
Emerging trends in bispecific antibody and scaffold protein therapeutics
Verdino, P., Atwell, S., & Demarest, S. J. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2018.01.004 · Cited by 12
Trifunctional Triomab® Antibodies for Cancer Therapy
Lindhofer, H., Heß, J., & Ruf, P. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_16 · Cited by 12
Targeting cytotoxic T cells to antigen‐specific B lymphocytes
Rammensee, H., Julius, M. H., Nemazee, D. A., Langhorne, J., Lamers, R., & Köhler, G. (1987) · European Journal of Immunology · doi:10.1002/eji.1830170322 · Cited by 12
A bispecific antibody recognizing influenza A virus M2 protein redirects effector cells to inhibit virus replication in vitro
Fernández-Sesma, A., Schulman, J. L., & Moran, T. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4800-4804.1996 · Cited by 12
Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.
Yoshino, I., Yano, T., Murata, M., Ishida, T., Sugimachi, K., Kimura, G., & Nomoto, K. (1991) · PubMed · Cited by 12
Bifunctional antibodies and their potential clinical applications
Nolan, O., & O’Kennedy, R. J. (1992) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02591389 · Cited by 12
Spontaneous human T-cell cytotoxicity against murine hybridomas expressing the OKT3 monoclonal antibody: Comparison with natural killer cell activity
Itoh, K., Balch, C. M., & Platsoucas, C. D. (1987) · Cellular Immunology · doi:10.1016/0008-8749(87)90215-2 · Cited by 12
Anti-tumor × anti-CD3 heteroconjugates direct human peripheral blood lymphocytes to lyse colon tumor cells
Nelson, H. D., McKEAN, D. J., Kerr, L. A., & Donohue, J. H. (1990) · Journal of Surgical Research · doi:10.1016/0022-4804(90)90060-f · Cited by 12
Targeting of peripheral blood T lymphocytes
Bolhuis, R. L. H., Hoogenboom, H. R., & Gratama, J. W. (1996) · Springer Seminars in Immunopathology · doi:10.1007/bf00820667 · Cited by 12
Antibodies from Escherichia coli
Plückthun, A. (1994) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-78432-3_11 · Cited by 12
Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study
Li, X., Dai, R., Xu, Q., Guo, Z., Hu, C., Sun, Y., Niu, Z., Hao, J., Zhang, M., Dai, G., et al. (2026) · BMC Medicine · doi:10.1186/s12916-025-04597-8 · Cited by 11
Targeting of Drugs to Cell Surface Receptors
Říhová, B. (1997) · Critical Reviews in Biotechnology · doi:10.3109/07388559709146611 · Cited by 11
Resting human peripheral blood lymphocytes can be activated to cytolytic function by antibodies to CD3 in the absence of exogenous interleukin-2
Scott, C. F., Lambert, J. M., Bolender, S., & Blättler, W. A. (1988) · Cellular Immunology · doi:10.1016/0008-8749(88)90329-2 · Cited by 11
Clinical immunotherapy for brain tumors
Fecci, P. E., & Sampson, J. H. (2002) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(02)00027-8 · Cited by 11
Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer.
Boerman, O. C., Tibben, J. G., Massuger, L. F. A. G., Claessens, R. A. M. J., & Corstens, F. H. (1995) · PubMed · Cited by 11
Harnessing Immune Response in Acute Myeloid Leukemia
Riva, C., Vernarecci, C., Minetto, P., Goda, R., Greppi, M., Pesce, S., Chies, M., Zecchetti, G., Ferro, B., Maio, E., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185824 · Cited by 10
Development of a novel bi-specific monoclonal antibody approach for tumour targeting
Koumarianou, A. A., Hudson, M., Williams, R., Epenetos, A. A., & Stamp, G. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690712 · Cited by 10
Novel antibody reagents: Production and potential
Williams, G. T. (1988) · Trends in biotechnology · doi:10.1016/0167-7799(88)90034-0 · Cited by 10
Regulation of clonal growth by anti-T-cell receptor antibody-directed lysis.
Berardinis, P. D., Londei, M., Carrel, S., & Feldmann, M. (1988) · PubMed Central · Cited by 10
The challenges of translation
Salih, H. R., & Jung, G. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910874 · Cited by 9
Impact of T-Cell Engagers on COVID-19–Related Mortality in B-Cell Lymphoma Patients Receiving B-Cell Depleting Therapy
Lee, C. M., Choe, P. G., Kang, C. K., Jo, H. J., Kim, N. J., Yoon, S., Kim, T. M., Park, W. B., & Oh, M. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.738 · Cited by 9
Purification and biochemical characterization of immunotoxins
Lambert, J. M., & Blättler, W. A. (1988) · Cancer treatment and research · doi:10.1007/978-1-4613-1083-9_18 · Cited by 9
Bispecific Antibody‐directed Antitumor Activity of Human CD4+Helper/Killer T Cells Induced by Anti–CD3 Monoclonal Antibody plus Interleukin 2
Nishimura, T., Nakamura, Y., Takeuchi, Y., Gao, X., Tokuda, Y., Okumura, K., & Sonoko, S. (1991) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1991.tb01782.x · Cited by 9
Genetically engineered antibodies for direct antineoplastic treatment and systematic delivery of various therapeutic agents to cancer cells
Bödey, B. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.4.603 · Cited by 9
Augmentation by Bispecific F(ab′)2 Reactive with P‐Glycoprotein and CD3 of Cytotoxicity of Human Effector Cells on P‐Glycoprotein Positive Human Renal Cancer Cells
Heike, Y., Okumura, K., & Tsuruo, T. (1992) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1992.tb00116.x · Cited by 9
Development and Validation of an Effi cient Real-time Quantitative Reverse Transcription Polymerase Chain Reaction Assay of Chinese Goose CD4 and CD8α
Zhao, Q., Chen, S., Liu, F., Qi, Y., Wang, M., Jia, R., Zhu, D., Liu, M., & Cheng, A. (2014) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 8
An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
Snell, D. C., Gunde, T., Warmuth, S., Chatterjee, B., Brock, M., Hess, C., Johansson, M. H., Simonin, A., Spiga, F. M., Weinert, C., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2233401 · Cited by 8
Synthesis of Bifunctional Antibodies for Immunoassays
Desilva, B. S., & Wilson, G. S. (2000) · Methods · doi:10.1006/meth.2000.1033 · Cited by 8
Interferon-gamma-induced intercellular adhesion molecule-1: expression on human tumor cells enhances bifunctional antibody-mediated lysis through a lymphocyte function-associated antigen-1 dependent mechanism.
Ramsey, P. S., Dean, P. A., Tasimowicz-Alpini, A., Donohue, J. H., & Nelson, H. D. (1993) · PubMed · Cited by 8
Targeting of cytotoxic cells with cross-linked antibody heteroaggregates
Segal, D. M., Pérez, P., Karpovsky, B., & Titus, J. A. (1986) · Molecular Immunology · doi:10.1016/0161-5890(86)90153-7 · Cited by 8
Self-citation
Concepts of Antibody-Mediated Cancer Therapy
KUMMER, U., & Staerz, U. D. (1993) · Cancer Investigation · doi:10.3109/07357909309024836 · Cited by 8
Lysis of CD3 hybridoma targets by cloned human CD4 lymphocytes.
Hayward, A. C., Boylston, A. W., & Beverley, P. C. L. (1988) · PubMed Central · Cited by 8
Generation of bispecific antibodies by structure-guided redesign of IgG constant regions
Iwasaki, Y. W., Tharakaraman, K., Subramanian, V., Khongmanee, A., Hatas, A., Fleischer, E., Rurak, T. T., Ngok-ngam, P., Tit-oon, P., Ruchirawat, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1063002 · Cited by 7
Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B
Xie, Z., & Protzer, U. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105972 · Cited by 10
Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells
He, Q., Zhang, H., Wang, Y., Ting, H. H., Yu, W., Cao, X., & Ge, W. (2014) · Cell & Bioscience · doi:10.1186/2045-3701-4-70 · Cited by 7
Bispecific Antibodies from Hybrid Hybridoma
Moldenhauer, G. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_2 · Cited by 7
Redirecting the Cellular Immune Response
Staerz, U. D., & Bevan, M. J. (1989) · International Reviews of Immunology · doi:10.3109/08830188909044779 · Cited by 7
Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells.
Scott, C. F., Blättler, W. A., Lambert, J. M., Kalish, R. S., Morimoto, C., & Schlossman, S. F. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113473 · Cited by 7
Ovarian Carcinoma Therapy with Monoclonal Antibodies
Canevari, S., Miotti, S., BUTTERO, F., Valota, O., & COLNAGHI, M. I. (1993) · Hybridoma · doi:10.1089/hyb.1993.12.501 · Cited by 7
Molecular Mechanisms of Cytotoxicity: Comparison of Complement and Killer Lymphocytes
Müller‐Eberhard, H. J., Zalman, L. S., Chiu, F. J., Jung, G., & Martin, D. E. (1986) · Elsevier eBooks · doi:10.1016/b978-0-12-174685-8.50030-5 · Cited by 7
Bispecific Antibodies
Wozniak‐Knopp, G. (2020) · Learning materials in biosciences · doi:10.1007/978-3-030-54630-4_7 · Cited by 6
9 Future treatment strategies: fact or fiction?
Schnell, R., Barth, S., Diehl, V., & Engert, A. (1996) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(96)80028-x · Cited by 6
The cytotoxic action of lymphokine activated killer cells upon the human glioma cell line U251 is stimulated by bispecific monoclonal antibody (MoAb) constructs
Obukhov, S., Gennie, M., Tutt, A. L., Kemshead, J. T., Coakham, H. B., & Beverley, P. C. L. (1992) · Journal of Neuro-Oncology · doi:10.1007/bf00172471 · Cited by 6
Cytokine Release by Peripheral Blood Lymphocytes Targeted with Bispecific Antibodies, and Its Role in Blocking Tumor Growth
Segal, D. M., Qian, J. H., Andrew, S. M., Titus, J. A., Mezzanzanica, D., GARRIDO, M. A., & Wunderlich, J. R. (1991) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1991.tb33459.x · Cited by 6
Self-citation
A novel strategy for immunotherapy using antibody‐coupled carriers to focus cytotoxic T helper cells
Ochi, A., Worton, K. S., Woods, G. M., Gravelle, M., & Kitagami, K. (1987) · European Journal of Immunology · doi:10.1002/eji.1830171119 · Cited by 6
Heteroconjugated antibodies enhance lymphocyte-mediated tumour cell lysis in vitro and in vivo
Reid, I. M., Lundy, J., Monson, J. R. T., Nelson, H., Ramsay, P., Ilstrup, D. M., & Donohue, J. H. (1992) · British journal of surgery · doi:10.1002/bjs.1800790710 · Cited by 6
The Development of Bispecific Hexavalent Antibodies as a Novel Class of DOCK-AND-LOCKTM (DNLTM) Complexes
Chang, C., Rossi, E., Wang, Y., Cardillo, T. M., & Goldenberg, D. M. (2013) · Antibodies · doi:10.3390/antib2020353 · Cited by 5
CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
Kauer, J., Vogt, F., Hagelstein, I., Hörner, S., Märklin, M., Maurer, S., Salih, H. R., Jung, G., & Zekri, L. (2021) · Cancers · doi:10.3390/cancers13184596 · Cited by 5
A New In Vitro Model of Specific Targeting Therapy of Cancer: Retargeting of PWM-LAK Cells with Bispecific Antibodies Greatly Enhances Cytotoxicity to Hepatocellular Carcinoma.
Saijyo, S., Kudo, T., Katayose, Y., Saeki, H., Chiba, N., Suzuki, M., Tominaga, T., & Matsuno, S. (1996) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.178.113 · Cited by 5
Targeting therapy for glioma by LAK cells coupled with bispecific antibodies
Hishii, M., Nitta, T., Ebato, M., Okumura, K., & Sato, K. (1994) · Journal of Clinical Neuroscience · doi:10.1016/0967-5868(94)90067-1 · Cited by 5
Synthetic immunity to break down the bottleneck of cancer immunotherapy
Chen, Z., Ma, F., Huang, H., & He, C. (2015) · 中国科学通报：英文版 · doi:10.1007/s11434-015-0794-z · Cited by 5
РЕКОМБИНАНТНЫЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА - ОТ ВИЗУАЛИЗАЦИИ ОПУХОЛЕЙ К ИММУНОТЕРАПИИ РАКА. КРИТИЧЕСКИЙ ОБЗОР, "Молекулярная биология"
Mach, J. P. (2017) · Molecular Biology · doi:10.7868/s0026898417060131 · Cited by 5
Engineering T lymphocyte antigen specificity
Bolhuis, R. L. H., Sturm, E., Gratama, J. W., & Braakman, E. (1991) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240470404 · Cited by 5
Targeted Cellular Cytotoxicity
Segal, D. M., Jost, C. R., & George, A. J. T. (1993) · Birkhäuser Boston eBooks · doi:10.1007/978-1-4684-6814-4_9 · Cited by 5
Self-citation
The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma
Robat-Jazi, B., Lorestani, P., Nejati, N., Ebrahimi, E., Habibi, M. A., Ahmadpour, M., Jokar-Derisi, A., Karimizadeh, Z., Bagheri, K., & Ahmadpour, S. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02057-y · Cited by 4
The potential role of Bi-specific antibodies in acute myeloid leukemia
Yilmaz, M. E., & Ravandi, F. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101218 · Cited by 4
[16] Design and production of bispecific monoclonal antibodies by hybrid hybridomas for use in immunoassay
Takahashi, M., Fuller, S. A., & Winston, S. (1991) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(91)03018-c · Cited by 4
The Dock-and-Lock (DNL) Approach to Novel Bispecific Antibodies
Chang, C., Rossi, E. A., Sharkey, R. M., & Goldenberg, D. M. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_12 · Cited by 4
CD8+ T cells lyse autologous monocytes in the presence of anti-CD3 monoclonal antibody: Association with interleukin-1 production
Itoh, K., Balch, C. M., Trial, J., & Platsoucas, C. D. (1988) · Cellular Immunology · doi:10.1016/0008-8749(88)90320-6 · Cited by 4
Development and prospects for bispecific antibody-based therapeutics in cancer and other applications
Lum, L. G., & Al-Kadhimi, Z. S. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.9.1081 · Cited by 4
Preparation and analysis of bifunctional immunoconjugates containing monoclonal antibodies OKT3 and BABR1
Foglesong, P. D., Winkler, M. A., Price, J. O., Marshall, G. D., Reagh, S. H., Bush, D. A., Hixson, K. S., & West, W. H. (1989) · Cancer Immunology Immunotherapy · doi:10.1007/bf01669427 · Cited by 4
Introduction to monoclonal antibodies.
Mach, J. (2012) · Europe PMC (PubMed Central) · Cited by 4
Characterization of a Novel Bispecific Antibody That Activates T Cells In Vitro and Slows Tumor Growth In Vivo
Chornoguz, O., Leettola, C. N., Leander, K. R., Brosnan, K., Emmell, E., Chiu, M. L., & Santulli-Marotto, S. (2019) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2019.0035 · Cited by 4
Target Cell Induced T Cell Activation with Bispecific Antibodies: A New Concept for Tumor Immunotherapy
Wolf, H., Freimann, U., & Jung, G. (1994) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-85039-4_18 · Cited by 4
Current approaches to vaccine preparation.
Liu, J.-J., & Cepica, A. (1990) · PubMed Central · Cited by 4
Role of the CD45 (T-200) molecule in anti-CD3-triggered T cell-mediated cytotoxicity
Deem, R. L., Shanahan, F., Niederlehner, A., & Targan, S. (1988) · Cellular Immunology · doi:10.1016/0008-8749(88)90080-9 · Cited by 4
Cytotoxic and proliferative allospecific T-cell clones contain perforin and mediate anti-CD3-induced cytotoxicity
Geisberg, M., Terry, L. A., Flomenberg, N., & Dupont, B. (1992) · Human Immunology · doi:10.1016/0198-8859(92)90005-8 · Cited by 4
Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody
Mansfield, P. F., Rosenblum, M. G., Murray, J. L., & Itoh, K. (1991) · Cancer Immunology Immunotherapy · doi:10.1007/bf01744944 · Cited by 4
Effectors of targeted cellular cytotoxicity
Segal, D. M., Garrido, M. A., Jia-Hua, Q., Mezzananica, D., Andrew, S. M., Pérez, P., Kurucz, I., Valdayo, M. J., Titus, J. A., Winkler, D. F., et al. (1990) · Molecular Immunology · doi:10.1016/0161-5890(90)90040-7 · Cited by 4
Self-citation
Treatment of patients with malignant lymphomas with monoclonal antibodies
Tesch, H., Engert, A., Manzke, O., Diehl, V., & Bohlen, H. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702355 · Cited by 4
Antibody-Mediated Cancer Diagnosis and Therapy
Bator, J. M., & Reading, C. L. (1990) · Palgrave Macmillan UK eBooks · doi:10.1007/978-1-349-11894-6_3 · Cited by 4
Unlocking the potential of T cell engagers in solid tumors
Wingrove, E., Bailis, J. M., Farago, A. F., & Soria, J. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.03.011 · Cited by 3
Role of targeting nanoparticles for cancer immunotherapy and imaging
Wen, R. M., & Umeano, A. C. (2017) · Trends in Immunotherapy · doi:10.24294/ti.v1.i3.95 · Cited by 3
Facile Access to Branched Multispecific Proteins
Okon, A. M., Yang, J., Giancola, J. B., Molina, O., Sayers, J., Cheah, K. M., Li, Y., Strieter, E. R., & Raines, R. T. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00162 · Cited by 3
T-cell engaging bispecific antibody therapy
Culp, P. A., Degenhardt, J. D., Dettling, D. E., & May, C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823397-9.00002-8 · Cited by 3
Bispecific antibodies: A promising entrant in cancer immunotherapy
Saini, S., & Kumar, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821972-0.00014-9 · Cited by 3
Bispecific Antibodies in Lymphoma
Brissinck, J., Demanet, C. J., Moser, M., Léo, O., & Thielemans, K. (1993) · International Reviews of Immunology · doi:10.3109/08830189309061695 · Cited by 3
11 Novel intravenous immunoglobulins and their applications
YAP, P. L., & Williams, P. E. (1990) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(05)80058-7 · Cited by 3
Monoclonal Antibodies in Cancer Immunotherapy
Reisfeld, R. A. (1992) · Clinics in Laboratory Medicine · doi:10.1016/s0272-2712(18)30513-4 · Cited by 3
Structural and functional analysis of engineered antibodies for cancer immunotherapy: insights into protein compactness and solvent accessibility
Saini, S., & Kumar, Y. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2300129 · Cited by 2
BCR/ABL, IKZF deletions and FLT3-ITD as the targets for relapsed/refractory B-cell acute lymphoblastic leukemia treatment: Blinatumomab combined with Tyrosine kinase inhibitors and ATRA
Соколов, А. Н., Parovichnikova, E. N., Troitskaya, V. V., Kuzmina, L. A., Galtseva, I. V., Kulikov, S. M., Bondarenko, S. N., Lukyanova, I. A., Lobanova, T. I., Usikova, E. I., et al. (2020) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2020-9-1-38-46 · Cited by 2
Measurement of Intercellular Conjugates by Flow Cytometry
Segal, D. M. (2001) · Current Protocols in Immunology · doi:10.1002/0471142735.im0506s14 · Cited by 2
Self-citation
Targeting of «T» Lymphocytes against Human Hepatoma Cells by a Bispecific Monoclonal Antibody: Role of Different Lymphocyte Subsets
Chen, Q., Sun, P., Prigione, I., Xie, H. J., & Ferrini, S. (1992) · Tumori Journal · doi:10.1177/030089169207800204 · Cited by 2
Nonclinical Development of Multi-targeting Biopharmaceuticals
Prell, R. A., Lee, D. W., Halpern, W., & Connor, A. V. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00014-9 · Cited by 2
Non-Hodgkinʼs Lymphoma
Schnell, R., Barth, S., Diehl, V., & Engert, A. (1997) · BioDrugs · doi:10.2165/00063030-199708030-00007 · Cited by 2
Cytotoxic lymphocyte‐mediated immunotherapy
Smyth, M. J., & Kershaw, M. H. (1995) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1995.tb02891.x · Cited by 2
Les anticorps bispécifiques : une vieille histoire pleine d’avenir… avec les CAR-T !
Riffard, C., & Teillaud, J. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.02.016 · Cited by 2
Bispecific Antibodies for Arming Activated T Cells and Other Effector Cells for Tumor Therapy
Lum, L. G., & Thakur, A. B. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_14 · Cited by 2
Recombinant Monoclonal Antibodies, from Tumor Targeting to Cancer Immunotherapy: A Critical Overview
Mach, J. P. (2017) · Molecular Biology · doi:10.1134/s0026893317060115 · Cited by 2
Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé
Szakács, Z., & Alizadeh, H. (2022) · Hematológia–Transzfuziológia · doi:10.1556/2068.2022.00151 · Cited by 2
Molecular engineering of high affinity T-cell receptors for bispecific therapeutics
Liddy, N. (2013) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 2
The New Antibody Technologies
Lillehoj, E. P., & Malik, V. S. (1993) · Advances in applied microbiology · doi:10.1016/s0065-2164(08)70216-8 · Cited by 2
Bispecific antibodies for the treatment of tumours and infectious diseases
Drakeman, D. L., Fanger, M. W., & Wallace, P. K. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.9.1169 · Cited by 2
The bispecific antibody 500A2 × 96.5 targets T-lymphocytes activated in vivo with staphylococcal enterotoxin B (SEB) against CL62 melanoma cells in vitro
Reid, I. M., Lundy, J., & Donohue, J. H. (1994) · Surgical Oncology · doi:10.1016/0960-7404(94)90030-2 · Cited by 2
Antibody-based diagnostic and therapeutic innovations for human cancer
Kramer, K., & Cheung, N. V. (2001) · Comprehensive Therapy · doi:10.1007/s12019-001-0013-5 · Cited by 2

Authors: Perez, P., Hoffman, R. W., Shaw, S., Bluestone, J. A., & Segal, D. M.
Affiliations: National Institutes of Health (US)
ORCID: Shaw, Stephen
Bluestone, Jeffrey A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1985-07
Volume: 316
Issue: 6026
Pages: 354-356
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/316354a0
OpenAlex: W2065272367
Cited by: 337
References: 23
Citations by year: 2026: 4 · 2024: 10 · 2023: 7 · 2022: 7 · 2021: 17 · 2020: 9 · 2019: 7 · 2018: 10 · 2017: 6 · 2016: 6 · 2015: 4 · 2014: 11 · 2013: 6 · 2012: 6
FWCI: 22.63
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: cytotoxic T lymphocytes, T cell receptor, antibody-dependent cellular cytotoxicity, heteroaggregates, T cell specificity, chicken erythrocytes, T cell cytotoxicity
MeSH terms: Animals, Antibodies, Antibodies, Monoclonal, Antibody Specificity, Antibody-Dependent Cell Cytotoxicity, Antigens, Surface, Clone Cells, Glycoproteins, Histocompatibility Antigens, Humans, Receptors, Antigen, T-Cell, T-Lymphocytes, Cytotoxic, CD3 Complex, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks